Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics save search
Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules
Published: 2023-01-27 (Crawled : 23:00) - biospace.com/
IKT | News 0 d | $0.69 -2.82% -2.9% 420K
|
Health Technology
|
| O: -2.82%
H: 0.0%
C: 0.0%
offering nasdaq therapeutics direct market
ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-01-27 (Crawled : 22:00) - globenewswire.com
ZVSA | News | $2.1 -2.33% -2.38% 51K
|
| Email alert
Add to watchlist
nasdaq grant medical therapeutics
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Published: 2023-01-27 (Crawled : 22:00) - globenewswire.com
PLRX | News M 0 d | $34.87 -3.83% -3.99% 1M
|
Health Technology
| Email alert
Add to watchlist
offering therapeutics
Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals
Published: 2023-01-27 (Crawled : 21:00) - biospace.com/
QNCX | News | $1.1 36.14% 26.55% 64M
|
Professional, Scientific, and T...
|
| O: 54.7%
H: 0.0%
C: 0.0%
pharmaceuticals therapeutics
Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Published: 2023-01-27 (Crawled : 19:00) - globenewswire.com
JSPR | News S 1 d | $1.73 -3.89% -4.05% 1.1M
|
| Email alert
Add to watchlist
offering therapeutics
Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
Published: 2023-01-27 (Crawled : 17:00) - globenewswire.com
FBIO | News | $0.9122 2.49% 2.43% 450K
|
Health Technology
|
| O: 4.54%
H: 0.0%
C: 0.0%
ATXI | News | $1.36 -12.26% -13.97% 1M
|
Health Technology
|
| O: -10.97%
H: 0.0%
C: 0.0%
nasdaq therapeutics direct market
Altamira Therapeutics Provides Business Update
Published: 2023-01-27 (Crawled : 14:00) - globenewswire.com
CYTO | News | $2.78 -12.58% -14.39% 170K
|
Manufacturing
|
| O: -13.77%
H: 0.0%
C: 0.0%
therapeutics update
Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock
Published: 2023-01-26 (Crawled : 22:00) - ir.agiletherapeutics.com
AGRX | $0.2639 -13.76% -15.95% 1.9M
|
Health Technology
| Email alert
Add to watchlist
distribution therapeutics
invoX Pharma and F-star Therapeutics issue Joint Statement
Published: 2023-01-26 (Crawled : 21:00) - globenewswire.com
FSTX | $4.195 -3.12% -3.22% 1.1M
|
Health Technology
| Email alert
Add to watchlist
pharma therapeutics
Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders
Published: 2023-01-26 (Crawled : 15:00) - biospace.com/
PEAR S | $1.085 -9.58% -10.6% 370K
|
Professional, Scientific, and T...
|
| O: 2.68%
H: 6.96%
C: 4.35%
treatment for health program therapeutics
Onconova Therapeutics Announces Participation in the Channelchek Takeaway Series
Published: 2023-01-26 (Crawled : 14:20) - biospace.com/
ONTX | $0.85 -1.78% -1.81% 74K
|
Health Technology
|
| O: 0.12%
H: 3.57%
C: 3.02%
therapeutics
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome
Published: 2023-01-26 (Crawled : 14:00) - globenewswire.com
SLNO A | $2.83 9.27% 8.48% 110K
|
Health Technology
|
| O: -1.24%
H: 32.22%
C: 8.37%
treatment for trial therapeutics results publication
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
Published: 2023-01-26 (Crawled : 14:00) - globenewswire.com
TGTX | $14.63 3.39% 3.28% 4M
|
Health Technology
|
| O: 3.13%
H: 0.34%
C: -2.28%
treatment for commercial therapeutics sclerosis
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Published: 2023-01-26 (Crawled : 13:20) - biospace.com/
CTMX | $2.775 -0.18% -0.18% 1.4M
|
Health Technology
|
| O: 1.11%
H: 6.57%
C: 1.46%
probody collaboration t-cell therapeutics milestone
Apogee Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer
Published: 2023-01-26 (Crawled : 12:20) - prnewswire.com
HBCYF | $7.43 0
|
Finance
|
| O: 1.48%
H: 0.65%
C: 0.54%
HSBC | $37.15 -0.88% -0.8% 1.8M
|
Finance
|
| O: 1.17%
H: 0.83%
C: 0.78%
CM 3 d | $44.63 1.18% 0.0% 830K
|
Finance
|
| O: 0.64%
H: 0.56%
C: 0.46%
therapeutics financial
HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders
Published: 2023-01-26 (Crawled : 02:00) - prnewswire.com
SNYNF | News | $97.85 0
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
SNY | News | $48.49 -0.66% -0.66% 1.1M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
for endocrine therapeutics
Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules
Published: 2023-01-25 (Crawled : 23:00) - biospace.com/
IKT | News 0 d | $0.69 -2.82% -2.9% 420K
|
Health Technology
|
| O: 5.35%
H: 0.0%
C: 0.0%
offering nasdaq therapeutics direct market
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety
Published: 2023-01-25 (Crawled : 21:00) - globenewswire.com
MGTA | $0.4624 5.07% 4.82% 930K
|
Health Technology
|
| O: -18.5%
H: 15.98%
C: 13.43%
mgta-117 drug trial therapeutics
Global Psoriasis Therapeutics Market Report to 2031 - Featuring Abbvie, Amgen, Bausch Health, LEO Pharma and Novan Among Others
Published: 2023-01-25 (Crawled : 21:00) - prnewswire.com
NVSEF | News 4 d | $90.0 0
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
VTRS | $11.89 2.15% 2.1% 9.9M
|
Health Technology
|
| O: 0.0%
H: 0.87%
C: 0.69%
NVS | News 4 d | $89.49 -0.39% 0.01% 1.7M
|
Health Technology
|
| O: -1.25%
H: 0.0%
C: 0.0%
LLY | News | $342.1 -1.7% 0.12% 2.3M
|
Health Technology
|
| O: 1.48%
H: 0.34%
C: -0.85%
BHC | $8.38 -1.64% 0.0% 4.7M
|
Health Technology
|
| O: 2.77%
H: 3.28%
C: -0.23%
ABBV | News | $146.28 -0.76% 0.06% 4.6M
|
Health Technology
|
| O: 0.15%
H: 0.0%
C: 0.0%
AMGN | News | $253.68 -0.47% -0.47% 2.1M
|
Health Technology
|
| O: -1.76%
H: 0.0%
C: 0.0%
leo pharma global report therapeutics psoriasis market
Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
Published: 2023-01-25 (Crawled : 15:20) - biospace.com/
HOTH | $4.8 -2.44% -2.5% 120K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
for trial therapeutics therapy cancer growth
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.